Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To compare blood pressure (BP) and safety outcomes in patients with hypertension initiating bisoprolol, versus other β-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium channel blockers or diuretics. Materials & methods: New user cohort study. Patients initiating bisoprolol were matched with up to four patients, in each comparator cohort using propensity score. BP outcomes were compared using linear mixed models and safety outcomes using Cox proportional hazards. Results: Differences in average systolic and diastolic BP variation were ≤3 mmHg between bisoprolol versus the compared classes. No difference was observed in risk of diabetes, obesity or erectile dysfunction. An increased dyslipidemia risk was only observed versus diuretics (hazard ratio: 0.76; 98.75% CI: 0.58, 0.99). Conclusion: No differences in BP variation and safety outcomes.
Supplementary Material
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39(33), 3021–3104 (2018).
• European guidelines for the treatment of hypertension.
2.
NICE. Hypertension in adults: diagnosis and management 2019. https://www.nice.org.uk/guidance/ng136
• UK guidelines for the treatment of hypertension.
3.
Law MR, Wald NJ, Morris JK et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
4.
Bronsert MR, Henderson WG, Valuck R et al. Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. J. Am. Board Fam. Med. 26(5), 529–538 (2013).
•• Non interventional study, with a different design and statistical methods, shows similar mean reduction in systolic blood pressure at 6-month, between the major antihypertensive classes.
5.
Wiysonge CS, Bradley HA, Volmink J et al. Beta-blockers for hypertension. Cochrane Database Syst. Rev. 1, CD002003 (2017).
6.
do Vale GT, Ceron CS, Gonzaga NA et al. Three generations of β-blockers: history, class differences and clinical applicability. Curr. Hypertens. Rev. 15(1), 22–31 (2019).
7.
Sabido M, Hohenberger T, Grassi G. Pharmacological intervention in hypertension using beta-blockers: real-world evidence for long-term effectiveness. Pharmacol. Res. 130, 191–197 (2018).
8.
Stoschitzky K. Betablockers in hypertension: acquiring a balanced view. Cardiovasc. Pharmacol. Pharmacoth. 8, (2010).www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-8/Betablockers-in-hypertension-acquiring-a-balanced-view
9.
CPRD. Clinical Practice Research Datalink 2020. https://www.cprd.com/
10.
Herrett E, Gallagher AM, Bhaskaran K et al. Data resource profile: clinical practice research datalink (CPRD). Int. J. Epidemiol. 44(3), 827–836 (2015).
11.
Sheppard JP, Schwartz CL, Tucker KL et al. Modern management and diagnosis of hypertension in the United Kingdom: home care and self-care. Ann. Glob. Health 82(2), 274–287 (2016).
12.
Weir S, Juhasz A, Puelles J et al. Relationship between initial therapy and blood pressure control for high-risk hypertension patients in the UK: a retrospective cohort study from the THIN general practice database. BMJ Open 7(7), e015527 (2017).
13.
Booth HP, Prevost AT, Gulliford MC. Validity of smoking prevalence estimates from primary care electronic health records compared with national population survey data for England, 2007 to 2011. Pharmacoepidemiol. Drug Saf. 22(12), 1357–1361 (2013).
14.
Matcho A, Ryan P, Fife D et al. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 37(11), 945–959 (2014).
15.
NHS. Read Codes 2020 [updated 19 October 2020; March 2021]. https://digital.nhs.uk/services/terminology-and-classifications/read-codes
16.
Spruance SL, Reid JE, Grace M et al. Hazard ratio in clinical trials. Antimicrob. Agents Chemother. 48(8), 2787–2792 (2004).
17.
McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychologic. Meth. 9(4), 403 (2004).
18.
Kupelian V, Hall SA, McKinlay JB. Common prescription medication use and erectile dysfunction: results from the Boston Area Community Health (BACH) survey. BJU Int. 112(8), 1178–1187 (2013).
19.
Patel JP, Lee EH, Mena-Hurtado CI et al. Evaluation and management of erectile dysfunction in the hypertensive patient. Curr. Cardiol. Rep. 19(9), 1–11 (2017).
20.
Hagberg KW, Divan HA, Persson R et al. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ 354, i4823 (2016).
21.
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167(4), 268–274 (2017).
22.
Mathur M, Ding P, Riddell C et al. Website and R package for computing E-values. Epidemiology 29(5), e45–e47 (2018).
23.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J. Hypertens. 33(2), 195–211 (2015).
•• Meta-analysis of randomized clinical trial showing non clinically significant differences in systolic blood pressure between the major antihypertensive classes.
24.
Stapff M, Hilderbrand S. First-line treatment of essential hypertension: a real-world analysis across four antihypertensive treatment classes. J. Clin. Hypertens. (Greenwich) 21(5), 627–634 (2019).
•• Non interventional study, with a different design and statistical methods, shows similar mean reduction in systolic blood pressure at 3-year, between the major antihypertensive classes.
25.
Channaraya V, Marya RK, Somasundaram M et al. Efficacy and tolerability of a beta-1 selective beta blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open 2(3), e000683 (2012).
26.
Zhou WJ, Wang RY, Li Y et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS ONE 8(9), e72102 (2013).
27.
Suojanen L, Haring A, Tikkakoski A et al. Haemodynamic influences of bisoprolol in hypertensive middle-aged men: a double-blind, randomized, placebo-controlled cross-over study. Basic Clin. Pharmacol. Toxicol. 121(2), 130–137 (2017).
28.
Cooper--DeHoff RM, Bird ST, Nichols GA et al. Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study. J. Am. Heart Assoc. 2(3), e000125 (2013).
• In a nested case–control study, β-blockers and diuretics comparatively increased the risk of Type 2 diabetes mellitus.
29.
Shen L, Shah BR, Reyes EM et al. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 347, f6745 (2013).
• In a randomized clinical trial, β-blockers and calcium channel blockers were not associated with the risk of Type 2 diabetes mellitus, whereas the risk was increased with diuretics.
30.
Reiner Ž, Catapano AL, De Backer G et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32(14), 1769–1818 (2011).
31.
Musini VM, Nazer M, Bassett K et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst. Rev. 29(5), CD003824 (2014).
32.
Oh PC, Kang WC, Moon J et al. Anti-anginal and metabolic effects of carvedilol and atenolol in patients with stable angina pectoris: a prospective, randomized, parallel, open-label study. Am. J. Cardiovasc. Drugs 16(3), 221–228 (2016).
33.
Weir MR, Moser M. Diuretics and β-blockers: is there a risk for dyslipidemia? Am. Heart J. 139(1), 174–184 (2000).
34.
Ozbilen S, Eren MA, Turan MN et al. The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism. Endocr. Res. 37(3), 117–123 (2016).
35.
Lee P, Day R, Greenfield J et al. Formoterol, a highly β 2-selective agonist, increases energy expenditure and fat utilisation in men. Int. J. Obes. 37(4), 593–597 (2013).
36.
Kovačić D, Marinšek M, Gobec L et al. Effect of selective and non-selective β-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin. Res. Cardiol. 97(1), 24–31 (2008).
37.
Rosen RC, Fisher WA, Eardley I et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: i. Prevalence of erectile dysfunction and related health concerns in the general population. Curr. Med. Res. Opin. 20(5), 607–617 (2004).
38.
Al Khaja KA, Sequeira RP, Alkhaja AK et al. Antihypertensive drugs and male sexual dysfunction: a review of adult hypertension guideline recommendations. J. Cardiovasc. Pharmacol. 21(3), 233–244 (2016).
39.
Baumhäkel M, Schlimmer N, Kratz M et al. Cardiovascular risk, drugs and erectile function–a systematic analysis. Int. J. Clin. Pract. 65(3), 289–298 (2011).
40.
Silvestri A, Galetta P, Cerquetani E et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur. Heart J. 24(21), 1928–1932 (2003).
41.
Manolis A, Doumas M, Ferri C et al. Erectile dysfunction and adherence to antihypertensive therapy: focus on β-blockers. Eur. J. Intern. Med. 81, 1–6 (2020).
Information & Authors
Information
Published In
Pages: 423 - 436
PubMed: 35189710
Copyright
© 2022 Merck KGaA, Germany. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 17 December 2021
Accepted: 9 February 2022
Published online: 22 February 2022
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0305
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Oleksandr Pyvovarov, Assessment of interest in drugs based on the active ingredient bisoprolol using the Google Trends search engine, The Ukrainian Scientific Medical Youth Journal, 10.32345/USMYJ.1(160).2026.7-17, 160, 1, (7-17), (2026).
- Hriday Kumar Chopra, Kamal Kumar Sethi, Tiny Nair, Chandrashekhar Ponde, Saumitra Ray, Sarita Rao, Shanmunga Sundaram, Dinesh Khullar, Navin C Nanda, Jatinder Pal Singh Sawhney, Sarita Bajaj, Yatin Mehta, Ashok Kumar Pancholia, Pradeep Jain, Ashok Kumar Omar, Aditya Kapoor, Rishi Sethi, Atul Abhyankar, Vinod Sharma, Anil Dhall, Ajay Sinha, Shishu Shankar Mishra, Satya Narayan Rautray, Gyarsi Lal Sharma, Ashwani Mehta, Rajeev Agarwala, Rajeev Rajput, Ajay Mahajan, Sanjay Porwal, Ramesh Hotchandani, Vishal Rastogi, Rajiv Passey, Mohan Bhargava, Gnanaraj Justin Paul, Dorairaj Prabhakaran, Vivudh P Singh, Vinod Mittal, Vitull Gupta, Anil Kumar Bhalla, Virender Kumar Katyal, Ishwarappa Balekundri Vijaylakshami, Asha Moorthy, Poonam Malhotra, Vanita Arora, Mona Bhatia, Prabhavathy Bhat, Shibba T Chhabra, Sugandhi Gopal, Tripti Deb, Preeti Gupta, Hemlata Tewari, Anupam Goel, Rekha Mishra, Lovelina Singh, Zakia Khan, Geeta Sheth, Chandra Mukhi, Inder Pal Singh Kalra, Yogender Kumar Arora, Uttara Das, Kavita Tyagi, Satya Nand Pathak, Samir Kubba, Saurabh Bagga, Asha Mahilmaran, Ameet Sattur, Rohit Tandon, Dharmender Jain, Hetan Shah, Cecily Majella, Ravi Prakash, Manish Aggarwal, Ruchi Verma, Sumit Sethi, Alka Gujral, Kanika Sood, Sonia Rawat, Varsha Kaul, Surinder S Arora, Manjiti Arora, Veena Bhat, Anil Kumar Bali, Sanjay Sood, Shakuntala Dawesar, Bhushan K Dawesar, Nilakshi Deka, Makarand Paithankar, Rajiv Handa, Nitish Parmar, Sheikh U Nabi, Naveen Garg, Sandeep Sharma, Vivek Tandon, Manoj Pabrai, Samshad Alam, Manju Tyagi, Manisha Sahay, Manju Hotchandani, Anupama Kathpalia, Ish Kathpalia, Sangeeta Chaudhary, Kiran Kukreja, Vikas Agrawal, Inam D Khan, Prachi Garg, Satya Naryana, Pawan Kumar Mangla, Rajiv Mehrotra, Rajiv Garg, Upadhyayula Satyanarayan, Himani Malhotra, Kapil Kumar, Lokesh Raj, Shachi Kalyani, Vijay Garg, Ali H Khan, Harman P Singh, Sajal Gupta, TC Singh, Vipul Rastogi, Rahul Ramteke, Sukriti Bhalla, Ritesh Sanguri, Sumit K Niranjan, Rohit Singla, Alok Kumar, Anu Grover, National Consensus Statement on Role of Bisoprolol across Cardiovascular Continuum: Special Focus on Women, Journal of The Association of Physicians of India, 10.59556/japi.73.0957, 73, 5, (e16-e33), (2025).
- V. S. Chulkov, M. Z. Gasanov, O. V. Azovtseva, E. E. Minina, Vl. S. Chulkov, The role of beta blockers in the treatment of cardiovascular diseases, Meditsinskiy sovet = Medical Council, 10.21518/ms2024-467, 16, (28-36), (2024).
- Antoine Pinon, Arthur Allignol, Thilo Hohenberger, Caroline Foch, Emmanuelle Boutmy, Ulrike Hostalek, Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practice Research Datalink cohort study, Journal of Comparative Effectiveness Research, 10.57264/cer-2023-0027, 13, 11, (2024).
- Petra Vysočanová, Optimal heart rate value - not only hypertensive patients, Medicína pro praxi, 10.36290/med.2024.013, 21, 2, (79-83), (2024).
- Felix Mahfoud, Jiguang Wang, Saumitra Ray, The current position of β-blockers in hypertension: guidelines and clinical practice, Current Medical Research and Opinion, 10.1080/03007995.2024.2318003, 40, sup1, (25-32), (2024).
- Ujwala Desai, Smita Pimple, Divya Dhamankar, Ganesh Desai, Vishal Vare, Developing a Green UV-Spectroscopic Method for Quercetin and Celecoxib Estimation Using AGREE Assessment Tool, International Journal of Pharmaceutical And Phytopharmacological Research, 10.51847/G4jD6FEZ1I, 14, 4, (9-16), (2024).
- Stefano Masi, Zhanna Kobalava, Chiara Veronesi, Elisa Giacomini, Luca Degli Esposti, Konstantinos Tsioufis, A Retrospective Observational Real-Word Analysis of the Adherence, Healthcare Resource Consumption and Costs in Patients Treated with Bisoprolol/Perindopril as Single-Pill or Free Combination, Advances in Therapy, 10.1007/s12325-023-02707-7, 41, 1, (182-197), (2023).
- Laura Dormer, Journal of Comparative Effectiveness Research: 2022 year in review, Journal of Comparative Effectiveness Research, 10.57264/cer-2023-0026, 12, 4, (2023).